China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...

Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster ...

Now, with its launch in Australia this month, and a recent approval for sale in the world’s biggest country, China ... So ...

A court in Ningxiang, Hunan province, has sentenced three people up to 11 years in prison and levied fines of 2.73 million ...

At least 28 companies mostly in China, are registered with ... including overhead and other costs. While Ozempic or Wegovy patients use a Novo Nordisk device to inject the drug, patients using ...

says Novo Nordisk, the Danish pharma company developing the drug. The drug mimics glucagon, which is the hormone also imitated by the cutting-edge GLP-1 diabetes and weight-loss drugs Ozempic and ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

The United Arab Emirates does not expect to resume talks with the U.S. about a multi-billion dollar deal for F-35 warplanes, ...

Novo Nordisk's Wegovy, a weight loss therapy, is one of the leaders in this fast-growing market. Ozempic, another famous ... approved in the European Union, China, and Japan (where it is called ...